Tradestie Institutional Equity Comparison Engine · Market Close May 04, 2026

ABPWW vs SGMO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SGMO Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 10–0 Matrix Metrics)

SGMO Overall Winner 6-Pillar Tally: ABPWW 0 – 5 SGMO (1 Tie) Matrix Metrics: ABPWW 0 – 10 SGMO

As of May 04, 2026, Sangamo Therapeutics, Inc. (SGMO) is the stronger overall head-to-head candidate over Abpro Holdings, Inc. Warrant (ABPWW) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABPWW carries a Unified Composite Score of 45.0/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin), whereas SGMO carries 52.0/100 (HOLD) at $0.18 (0.4x Forward P/E, -175.5% operating margin).

  • Technical & Structure Timing Caution: ABPWW trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile SGMO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ABPWW vs SGMO
ABPWW NASDAQ
Abpro Holdings, Inc. Warrant
Institutional Equity
$0.01
+0.0% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -1.56β · 265% Vol
Unified Composite Score
45.0 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
SGMO NASDAQ Head-to-Head Winner
Sangamo Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.18
+31.56% 1D
Market Cap $55.9M
TTM Revenue $40M
Forward P/E 0.4x
Beta / 30D Vol 1.49β · 206% Vol
Unified Composite Score
52.0 / 100 HOLD
Tech 25.0 Fund 46.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.4%), weak momentum, RSI 38
RSI-14: 38.4 · SMA20: $0.23 · SMA50: $0.31

6-Pillar Scorecard Institutional Category Breakdown (ABPWW 0 – 5 SGMO)

Columns: Metric · ABPWW · SGMO
1. Valuation Multiples SGMO
Forward P/E N/M 0.4x
Trailing P/E N/M 0.4x
PEG Ratio N/M N/M
EV / Revenue N/M 1.2x
2. Growth & Scale SGMO
Revenue Growth (YoY) N/A +88.4%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $40M
Market Cap N/A $55.9M
3. Profitability & Quality SGMO
Gross Margin N/A N/A
Operating Margin N/A -175.5%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -2891.8%
4. Balance Sheet & Cash Flow SGMO
Cash Generation (TTM) N/A -$90M
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $8.3M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SGMO
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 144.2% (71st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ABPWW (0) vs SGMO (10)
Institutional Metric ABPWW SGMO Criterion Row Edge
Market Capitalization
Scale
N/A $55.9M Larger Scale SGMO
Trailing P/E Ratio
Valuation
N/M 0.4x Lower Multiple SGMO
Forward P/E Ratio
Valuation
N/M 0.4x Lower Multiple SGMO
Revenue Growth (YoY)
Growth
N/A +88.4% Higher Growth SGMO
Operating Margin (TTM)
Profitability
N/A -175.5% Higher Margin SGMO
Net Profit Margin
Profitability
N/A 0.0% Higher Margin SGMO
Return on Equity (ROE)
Capital Efficiency
N/A -2891.8% Higher ROE SGMO
52-Week Range Position
Momentum
0% ($0–$0) 9% ($0–$1) Stronger Trend SGMO
Beta / 30D Volatility
Risk Regime
-1.56β · 265% Vol 1.49β · 206% Vol Lower Realized Risk SGMO
Unified Institutional Score
Composite Signal
45.0 / 100 (HOLD) 52.0 / 100 (HOLD) Higher Composite SGMO
Trailing 12M Revenue (USD)
Operating Scale
N/A $40M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$90M ($8.3M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SGMO +3.62 pp
ABPWW: -17.86% · SGMO: -14.24%
3M Horizon SGMO +12.68 pp
ABPWW: -58.33% · SGMO: -45.65%
6M Horizon SGMO +8.7 pp
ABPWW: -32.75% · SGMO: -24.05%
1Y Horizon ABPWW +8.96 pp
ABPWW: -39.79% · SGMO: -48.75%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABPWW vs SGMO. Trailing 12-month operating profitability (ABPWW N/A vs SGMO -175.5%) and valuation multiples (ABPWW N/M vs SGMO 0.4x Forward P/E) are benchmarked directly in Pillar 4 below.

ABPWW ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
SGMO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$40M
Gross MarginN/A
Op. Margin-175.5%
ROE / Fwd P/E-2891.8% · 0.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ABPWW UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ABPWW Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SGMO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 144.2%
IV Percentile 71st %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SGMO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ABPWW Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SGMO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $55.9M market capitalization and -175.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ABPWW vs SGMO Key Questions & Quantitative Answers

As of May 04, 2026, Sangamo Therapeutics, Inc. (SGMO) is the stronger overall head-to-head candidate over Abpro Holdings, Inc. Warrant (ABPWW) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABPWW carries a Unified Composite Score of 45.0/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin), whereas SGMO carries 52.0/100 (HOLD) at $0.18 (0.4x Forward P/E, -175.5% operating margin). Technical & Structure Timing Caution: ABPWW trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile SGMO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SGMO leads the Growth & Scale pillar: ABPWW posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with SGMO at +88.4% YoY revenue growth and +0.0% YoY earnings growth on $40M TTM revenue (N/A gross margin, -175.5% operating margin). On trailing 12-month operating scale, ABPWW generates N/A in USD-normalized revenue versus $40M for SGMO. In operating R&D and SG&A reinvestment, ABPWW deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SGMO.

SGMO screens cheaper on headline valuation multiples. ABPWW trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas SGMO trades at 0.4x Forward P/E, 0.4x Trailing P/E, N/M PEG, and 1.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABPWW (N/A ROE) versus SGMO (-2891.8% ROE) capital efficiency.

In options market volatility and institutional positioning, ABPWW carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-1.56β · 265% Vol realized risk). By comparison, SGMO carries 144.2% implied volatility (71st %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.49β · 206% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of May 04, 2026. For educational research only; not investment advice.